Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance

Bioventus Inc.

2022-Q2 EPS reported -$0.30 revenue$257,621,000

Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.
GAAP net loss of ($8.0M) vs ($10.8M) in Q2 2021; diluted loss per share ($0.11) vs ($0.10).
Adjusted EBITDA of $22.9M vs $19.9M YoY; Non-GAAP EPS $0.10 vs $0.11.
FY22 guidance narrowed: net sales $547.5-562.5M (mid-point unchanged); adjusted EBITDA $94-104M.
Discontinued MOTYS development; completed CartiHeal acquisition on July 12, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.